Vaxcyte (PCVX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.99

Estimate

-$2.11

Surprise

+5.7%

Score today

5.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Vaxcyte (PCVX) reported a narrower loss than forecast — adjusted EPS of -$1.99 against the -$2.11 estimate (a 5.7% beat on a still-unprofitable quarter).

• Vaxcyte, Inc. Stock 12-Month Price Target Adjusted by Analysts — fiscal.ai, 2026-11-05
• Vaxcyte Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-04
• Vaxcyte Says VAX-A1 Phase 1 Advances To Stage 2 At Low, Mid Doses Only; High-Dose Cohort Deferred Pending Further Safety — benzinga, 2026-11-04

TrendMatrix currently rates PCVX Sell at 5.5/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +5.7% surprise compares with a -9.4% four-quarter average. Next scheduled report: 2027-02-23.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$63.96

Price target

$102.05

Stop

$59.48

Upside to target

+59.6%

Reward-to-risk

6.2:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$9.75B

P/E (fwd)

-8.7

52-week range

$40.14–$90.75

Off 52-week high

29.5%

RSI (14)

51

Volume vs avg

0.15×

Score today

5.5/10